Akakura K, Isaka S, Fuse H, Akimoto S, Imai K, Yamanaka H, Akaza H, Niijima T, Moriyama N, Kawabe K
Ministry of Health and Welfare, Japan.
Hinyokika Kiyo. 1988 Jan;34(1):123-9.
Five hundred and sixty-five patients with prostatic cancer, who first visited 9 institutions in Japan between 1981 and 1985, were analyzed. The peak of age distribution was in the seventies. As clinical symptoms, disturbance on micturition was the most frequent and pain caused by metastasis was a complaint in approximately one tenth of the cases. Alkaline phosphatase measurement, prostatic biopsy, intravenous pyelography, bone scintigraphy, cystourethrography, and measurements of serum prostatic acid phosphatase and serum acid phosphatase were performed on more than 80% of the patients. The clinical stage was stage A1 in 6.2%, A2 in 3.7%, B in 14.9%, C in 20.7%, D1 in 7.4%, and D2 in 43.7%. According to the histological grade, well, moderately and poorly differentiated adenocarcinoma were observed in 20.4, 33.3 and 32.7%, respectively. Increased ratio of high grade to low grade was noticed in the lower age group as well as in the advanced stage. In this series, endocrine therapy was still accepted in most of the patients. Almost all were treated with hormonal medication and half of them had undergone bilateral orchiectomy. Surgery, radiation, chemotherapy or multidisciplinary therapy were attempted judging from the clinical stage and histological grade. However, old age restricted the therapeutic modality. Actuarial survival rate at 5 years for stage A1, A2, B, C, D1 and D2 was 89.2, 66.1, 72.7, 51.0, 47.5 and 28.0%, respectively. In the patients with stage D2, the 5-year actuarial rate of poorly differentiated adenocarcinoma was lower than that of well or moderately differentiated adenocarcinoma, even though more intensive therapy was given to the former.
对1981年至1985年间首次就诊于日本9家机构的565例前列腺癌患者进行了分析。年龄分布的峰值在七十岁。作为临床症状,排尿障碍最为常见,约十分之一的病例有转移引起的疼痛主诉。超过80%的患者进行了碱性磷酸酶测定、前列腺活检、静脉肾盂造影、骨闪烁显像、膀胱尿道造影以及血清前列腺酸性磷酸酶和血清酸性磷酸酶的测定。临床分期为A1期的占6.2%,A2期的占3.7%,B期的占14.9%,C期的占20.7%,D1期的占7.4%,D2期的占43.7%。根据组织学分级,高分化腺癌、中分化腺癌和低分化腺癌分别占20.4%、33.3%和32.7%。在低年龄组以及晚期患者中,高分级与低分级的比例增加。在本系列中,大多数患者仍接受内分泌治疗。几乎所有患者都接受了激素药物治疗,其中一半接受了双侧睾丸切除术。根据临床分期和组织学分级尝试进行手术、放疗、化疗或多学科治疗。然而,高龄限制了治疗方式。A1期、A2期、B期、C期、D1期和D2期患者的5年精算生存率分别为89.2%、66.1%、72.7%、51.0%、47.5%和28.0%。在D2期患者中,低分化腺癌的5年精算生存率低于高分化或中分化腺癌,尽管前者接受了更强化的治疗。